focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOncimmune Regulatory News (ONC)

Share Price Information for Oncimmune (ONC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 24.50
Bid: 23.00
Ask: 26.00
Change: 0.00 (0.00%)
Spread: 3.00 (13.043%)
Open: 24.50
High: 0.00
Low: 0.00
Prev. Close: 24.50
ONC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR's Dealing

5 Jun 2020 07:00

RNS Number : 0419P
Oncimmune Holdings PLC
05 June 2020
 

Oncimmune Holdings plc

 

("Oncimmune" or the "Company")

 

Director/PDMR's Dealing

 

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, was informed that, on 4 June 2020, dealings in the Company's ordinary shares of £0.01 each in the Company ("Ordinary Shares") by the following Director / PDMRs had occurred:

 

- Meinhard Schmidt, Non-Executive Chairman, together with his wife and PCA, Tatiana Schmidt, acquired in aggregate 13,000 Ordinary Shares at a weighted average price of £1.885 per share

 

- Tim Bunting, Non-Executive Director, acquired 150,000 Ordinary Shares at a weighted average price of £1.192 per share

 

- Adam Hill, Chief Executive Officer, acquired 8,481 Ordinary Shares at a price of £1.179 per share

 

- Matthew Hall, Chief Financial Officer, acquired 1,272 Ordinary Shares at a price of £1.179 per share

 

- Ron Kirschner, General Counsel and Company Secretary, acquired 1,652 Ordinary Shares at a price of £1.204 per share

 

 

Director/PDMR/ PCA

No. of Ordinary Shares acquired

Resulting interest

Resulting % holding

Meinhard Schmidt / Tatiana Schmidt

13,000

31,000

0.05%

Tim Bunting

150,000

2,956,717

4.7%

Adam Hill

8,481

40,913

0.06%

Matthew Hall

1,272

11,935

0.02%

Ron Kirschner

1,652

1,652

0.003%

 

This announcement, including the notification below, is made in accordance with the requirements of Article 19 of the EU Market Abuse Regulation.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

Meinhard Schmidt / Tatiana Schmidt

2

 

Reason for the notification

a)

 

Position/status

 

Non-executive Chairman / PCA

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Oncimmune Holdings plc

b)

 

LEI

213800HCYIWT6YPI1I02 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of £0.01 each

 

Identification code

ISIN: GB00BYQ94H38

b)

 

Nature of the transaction

Purchase of shares

c)

 

Price(s) and volume(s)

Price

Volume

£1.17

8,000

£1.21

5,000

d)

 

Aggregated information

- Aggregated volume

13,000 shares

Weighted average price of £1.885

- Price

e)

 

Date of the transaction 

4 June 2020

f)

 

Place of the transaction

London stock exchange, AIM

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

Timothy Bunting

2

 

Reason for the notification

 

a)

 

Position/status

 

Non-executive Director

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

Oncimmune Holdings plc

b)

 

LEI

213800HCYIWT6YPI1I02 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of £0.01 each

 

Identification code

ISIN: GB00BYQ94H38

b)

 

Nature of the transaction

 

Purchase of shares

c)

 

Price(s) and volume(s)

Price

Volume

£1.195

60,000

£1.19

90,000

d)

 

Aggregated information

- Aggregated volume

150,000 shares

Weighted average price of £1.192

- Price

e)

 

Date of the transaction 

4 June 2020

f)

 

Place of the transaction

London stock exchange, AIM

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

Dr Adam Mark Hill

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Executive Officer

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Oncimmune Holdings plc

b)

 

LEI

213800HCYIWT6YPI1I02 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of £0.01 each

 

Identification code

ISIN: GB00BYQ94H38

b)

 

Nature of the transaction

 

Purchase of shares

c)

 

Price(s) and volume(s)

Price

Volume

£1.179

8,481

d)

 

Aggregated information

- Aggregated volume

Same as above

- Price

e)

 

Date of the transaction 

4 June 2020

f)

 

Place of the transaction

 

London stock exchange, AIM

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

Matthew Hall

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Financial Officer

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Oncimmune Holdings plc

b)

 

LEI

213800HCYIWT6YPI1I02 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of £0.01 each

 

Identification code

ISIN: GB00BYQ94H38

b)

 

Nature of the transaction

Purchase of shares

c)

 

Price(s) and volume(s)

Price

Volume

£117.9

1,272

d)

 

Aggregated information

- Aggregated volume

Same as above

- Price

e)

 

Date of the transaction 

4 June 2020

f)

 

Place of the transaction

London stock exchange, AIM

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

Ron Kirschner

2

 

Reason for the notification

 

a)

 

Position/status

General Counsel and Company Secretary

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

Oncimmune Holdings plc

b)

 

LEI

213800HCYIWT6YPI1I02 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of £0.01 each

 

Identification code

ISIN: GB00BYQ94H38

b)

 

Nature of the transaction

Purchase of shares

c)

 

Price(s) and volume(s)

Price

Volume

£1.204

1,652

d)

 

Aggregated information

- Aggregated volume

Same as above

- Price

e)

 

Date of the transaction 

4 June 2020

f)

 

Place of the transaction

London stock exchange, AIM

 

 

For further information:

 

Oncimmune Holdings plc

Ron Kirschner, General Counsel and Company Secretary

contact@oncimmune.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHSSWESLESSEFM
Date   Source Headline
9th May 20243:08 pmRNSHolding(s) in Company
26th Apr 20247:00 amRNSAppointment of Nominated Adviser and Joint Broker
25th Apr 202410:44 amRNSHolding(s) in Company
2nd Apr 202411:34 amRNSResult of General Meeting
2nd Apr 20248:00 amRNSTotal Voting Rights
26th Mar 202411:18 amRNSHolding(s) in Company
13th Mar 20245:32 pmRNSBlock Listing Return
6th Mar 20243:02 pmRNSPosting of Notice of General Meeting
1st Mar 20241:00 pmRNSInvestor Presentation via Investor Meet Company
29th Feb 202411:19 amRNSHolding(s) in Company
29th Feb 20247:00 amRNSFinal Results
26th Feb 202411:30 amRNSResult of AGM
2nd Feb 20247:00 amRNSNotice of AGM
11th Dec 20233:12 pmRNSDirector/PDMR Shareholding
8th Dec 20232:31 pmRNSGrant of Options and PDMR Dealing
30th Nov 20237:00 amRNSProgress against Strategy
10th Nov 202310:14 amRNSHolding(s) in Company
7th Nov 20234:11 pmRNSGrant of Options and PDMR Dealing
19th Oct 20237:00 amRNSInvestor Presentation via Investor Meet Company
12th Oct 20237:00 amRNSUpdate on Strategy & Changes to the Board
1st Aug 20237:00 amRNSBoard Changes
14th Jul 20232:00 pmRNSCorrected unaudited interim results to 31 May 2022
12th Jul 20237:00 amRNSAppointment of new leadership team & board changes
26th Jun 202311:10 amRNSChange of registered office
23rd Jun 20237:00 amRNSTransition of Executive Leadership
15th Jun 20235:16 pmRNSCorrection to interim results
13th Jun 20237:45 amRNSHolding(s) in Company
5th Jun 20234:02 pmRNSDirector/PDMR Shareholding
31st May 20237:00 amRNSInterim Results
22nd May 20237:00 amRNSSale of Oncimmune Limited to Freenome
3rd Apr 20234:38 pmRNSHolding(s) in Company
27th Mar 202311:07 amRNSResult of GM
3rd Mar 20237:00 amRNSPosting of Annual Report and Notice of GM
27th Feb 20232:36 pmRNSResult of AGM
27th Feb 20237:00 amRNSFinal Results
23rd Feb 20237:00 amRNSAppointment of Joint Broker
17th Feb 20237:00 amRNSSiemens Healthineers Collaboration
3rd Feb 202311:50 amRNSNotice of AGM
31st Jan 20237:00 amRNSNotice of Results
13th Jan 20237:00 amRNSAppointment of Non-Executive Director
20th Dec 20227:00 amRNSImmunoINSIGHTS Trading Update
19th Dec 20221:35 pmRNSDirector/PDMR Shareholding
14th Dec 20222:00 pmRNSResult of Capital Raising
9th Dec 20221:30 pmRNSExtension of Capital Raising
7th Dec 20222:00 pmRNSProposed Placing and Subscription
4th Nov 20224:16 pmRNSGrant of Options and PDMR Dealing
21st Sep 20222:16 pmRNSPDMR Dealing
21st Sep 20227:00 amRNSUnaudited results for the 12 months to 31 May 2022
30th Aug 20223:53 pmRNSRevised Notice of Results
15th Aug 20222:06 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.